+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID06639854

Optimizing Letermovir Use to Prevent Cytomegalovirus in Hematopoietic Cell Transplant Patients By Monitoring Immune Response and Comparing Continuous vs. Interrupted Treatment

Led by M.D. Anderson Cancer Center · Updated on 2026-06-15

105

Participants Needed

1

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating whether stopping letermovir medication based on a patients immune response can better prevent cytomegalovirus CMV infections in patients who have received hematopoietic cell transplants HCT, compared to taking letermovir continuously every day. The study compares the effects of interrupting letermovir dosing guided by immune system tests against extending letermovir use up to 200 days after transplant, with additional monitoring up to one year. Important measures include infection rates, immune responses, medication use, mortality, and healthcare costs. Participants are randomly assigned to one of two groups. One group receives letermovir with possible pauses depending on immune test results showing their bodys response to CMV. The other group receives standard care with daily letermovir to prevent CMV infections. Both groups are monitored for outcomes including CMV infection occurrences, immune function, overall survival, and associated healthcare expenses from day 100 to day 365 post-transplant. During the study, participants undergo blood tests to assess immune responses and receive regular clinical evaluations for CMV infection and safety. Researchers track adverse events and mortality for about one year. The study collects data on letermovir use and patient health to determine if adjusting medication based on immunity improves outcomes and reduces drug exposure. Participants remain under close follow-up throughout the study period until completion.

CONDITIONS

Brief Title

The Use of Cytomegalovirus Cell Mediated Immunity to Optimize the Duration of Letermovir Prophylaxis in Hematopoietic Cell Transplant Recipients

Research Team

F

Fareed Khawaja, MBBS

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here